Impasse At US FDA Could Mean Stealth Abandons Barth Syndrome Treatment
Executive Summary
In an interview with the Pink Sheet, Stealth’s CEO says she is not confident the company could design a clinical trial in the rare disease that would meet the FDA’s expectations.